{
    "clinical_study": {
        "@rank": "117718", 
        "acronym": "GIRAFFE", 
        "arm_group": {
            "arm_group_label": "Cardiac arrhythmia symptoms", 
            "description": "All subjects enrolled in the study will have an iRhythm Zio patch placed and a blood sample obtained."
        }, 
        "biospec_descr": {
            "textblock": "A blood sample (in a 4 ml EDTA tube) for genotyping and a serum sample (in two 10ml red top\n      tubes) will be obtained from each patient."
        }, 
        "biospec_retention": "None Retained", 
        "brief_summary": {
            "textblock": "Our primary hypothesis is that a risk score comprised of approximately 10 single nucleotide\n      polymorphisms (SNPs) that are associated with atrial fibrillation at the Genome Wide\n      Association Study (GWAS) level is associated with the development of atrial fibrillation\n      among previously undiagnosed patients at high risk for atrial fibrillation. A current\n      example of these SNPs is shown in Table 1. As a secondary hypothesis, we will test the\n      association between atrial fibrillation diagnosed in this study with a subset of SNPs\n      reported to be associated with atrial fibrillation and with fine-mapping SNPs. We will also\n      test the association between atrial fibrillation of less than and greater than 30 seconds\n      and a panel of approximately 10 SNPs."
        }, 
        "brief_title": "THE GIRAFFE Study: Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Rhythm Monitoring", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients With Symptoms of Cardiac Arrhythmia at Risk for Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": [
                "Arrhythmias, Cardiac", 
                "Atrial Fibrillation"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptoms of high clinical suspicion for atrial fibrillation prompting referral for\n             ambulatory cardiac rhythm monitoring for potential atrial fibrillation.\n\n        AND\n\n          -  At high risk for atrial fibrillation, defined as any one of the following: ischemic\n             stroke with no defined etiology (In prior 6 months) [3, 4, 6, 7], hypertension [33],\n             increased body mass index (BMI >30kg/m2) [33], heart failure [33], clinically\n             significant murmur [33], prolonged PR interval on resting ECG [33], chronic kidney\n             disease [34], hypertrophic cardiomyopathy [35], congenital heart disease [36],\n             chronic obstructive pulmonary disease [37, 38], sleep apnea [39-41], thyroid disease\n             [42, 43], family history of atrial fibrillation [44], diabetes [45] or excess alcohol\n             consumption (Male > 14 drinks/week, Female >7 drinks/week)[46].\n\n          -  Age 40 years or older\n\n          -  Capable of providing informed consent\n\n          -  Capable of wearing a Zio Patch for up to 14 days\n\n          -  Capable of providing a blood sample\n\n        Exclusion Criteria:\n\n          -  Previously documented atrial fibrillation or atrial flutter.\n\n          -  Prior cardiac surgery (coronary artery bypass grafting, valve replacement or repair,\n             pericardial stripping, etc) within the past 30 days.\n\n          -  Hyperthyroidism.\n\n          -  Have known skin allergies, conditions, or sensitivities (e.g. allergy to adhesives,\n             psoriasis) as the Zio Patch should not be used on patients with known skin allergies,\n             conditions, or sensitivities.\n\n          -  Are receiving pacing therapy.\n\n          -  Are anticipated to receive or require external cardiac defibrillation during the\n             monitoring period.\n\n          -  Are anticipated to have exposure to high frequency surgical equipment during the\n             monitoring period."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients defined, as high risk for atrial fibrillation will be persons with:\n\n          1. No prior history of atrial fibrillation and/or atrial flutter (AFIB/AF) - with\n             symptoms of high clinical suspicion for AFIB/AF prompting referral for ambulatory\n             cardiac rhythm monitoring to evaluate for potential AFIB/AF, and\n\n          2. Any of the following features: ischemic stroke with no defined etiology (In prior 6\n             months) [3, 4, 6, 7], hypertension [33], increased body mass index (BMI >30kg/m2)\n             [33], heart failure [33], clinically significant murmur [33], prolonged PR interval\n             on resting ECG (>200msec) [33], chronic kidney disease [34], hypertrophic\n             cardiomyopathy [35], congenital heart disease [36], chronic obstructive pulmonary\n             disease [37, 38], sleep apnea [39-41], thyroid disease [42, 43], family history of\n             atrial fibrillation [44], diabetes [45] or excess alcohol consumption (Male > 14\n             drinks/week, Female >7 drinks/week)[46]."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970969", 
            "org_study_id": "13-6159"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Atrial Fibrillation", 
            "Cardiac monitoring", 
            "Genomics"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "contact": {
                "email": "anderson.eileen@scrippshealth.org", 
                "last_name": "Eileen Anderson"
            }, 
            "facility": {
                "address": {
                    "city": "La Jolla", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92037"
                }, 
                "name": "Scripps Clinic"
            }, 
            "investigator": {
                "last_name": "Douglas Gibson, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "This Study Will Investigate the Association Between a Set of Single Nucleotide Polymorphisms (SNPs) and Atrial Fibrillation in Patients at High Risk of Developing Atrial Fibrillation. The SNPs Investigated Will Have Been Previously Shown to be Associated With the Atrial Fibrillation.", 
        "overall_contact": {
            "email": "peters.melissa@scrippshealth.org", 
            "last_name": "Missy Peters"
        }, 
        "overall_official": {
            "affiliation": "Scripps Translational Science Institute", 
            "last_name": "Eric Topol, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "SNP effect sizes and frequencies were determined from the literature and the International HapMap Project database as indicated in Table 1. Expected occurrences of atrial fibrillation in the two groups were calculated using reference to previous studies as outlined above [7, 8, 33]. We expect 80 atrial fibrillation events in a 650 high-risk patients [48, 49]. Using these event rates and an alpha error of 5%, the power to detect an association between a 10-SNPs risk score and atrial fibrillation is >90%. The power to detect association between a 4-SNP risk score and atrial fibrillation is >80%.", 
            "measure": "Association between events of Atrial Fibrillation and 4-SNP risk score", 
            "safety_issue": "No", 
            "time_frame": "One time"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970969"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Scripps Translational Science Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Quest Diagnostics", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Scripps Translational Science Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}